Europe Epirubicin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Dosage (10mg/Vial, 50mg/Vial, 100mg/Vial, and 200mg/Vial), Application (Breast Cancer, Liver Cancer, Bladder Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
The Europe epirubicin market is expected to grow from US$ 51,079.61 thousand in 2022 to US$ 62,495.08 thousand by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.
Increasing Awareness Regarding Cancer Drive Epirubicin Market
On March 8, 2021, the World Health Organization introduced the Global Breast Cancer Initiative to reduce breast cancer mortality by 2.5% annually until 2040, thereby preventing an estimated 2.5 thousand deaths. This initiative was presented on International Women's Day by the WHO in an advocacy event, "Hearing the call of women with breast cancer." Similarly, the WHO Global Initiative for Childhood Cancer was launched in September 2018 to increase the survival rate of children with cancer by ~60% by 2030 while reducing suffering and improving quality of life of these children. World Cancer Day held every February 4 since 2000, is the uniting initiative led by the Union for International Cancer Control (UICC). The UICC focuses on raising worldwide cancer awareness; improving education; catalyzing personal, collective, and government actions; and working together for the purpose of preventing cancer deaths. Therefore, increasing cancer awareness through various initiatives is driving the epirubicin market across Europe.
Market Overview
Europe held the second-largest share in the epirubicin market owing to factors such as the rising prevalence of cancer and the high demand for developing new chemotherapy drugs. The market growth is attributed to the increasing pharmaceutical production, growing product innovations by pharmaceutical companies, rising government support, and development of production facilities and infrastructures. In addition, growing funding for research & development activities in the pharmaceutical industry is likely to offer many opportunities in the coming years. The pharmaceutical industry is continuously expanding in the UK. According to Office National Statistics, 610 companies were operating in the UK in 2018, and has over 15 global companies headquartered in the UK. Also, approximately 41% of pharmaceutical production is exported to other European countries and regions. Companies such as Astra Zeneca, Eli Lilly, and GSK have contributed significantly to the growth of pharmaceuticals by leading research & development activities. The growth of these companies is expected to influence the market growth in the coming years. Moreover, the incidence rate of breast cancer in the UK is highest in people aged 90 or above. As per the Office for National Statistics national statistics (UK), in 2019, ~605,181 people were aged 90 years and over. Further, as per Cancer Research UK, every year, there are ~55,900 new breast cancer cases in the UK. As a result, the growing geriatric population is likely to increase the incidence rate of breast cancer. Thus, the factors mentioned above are driving the epirubicin market growth.
Europe Epirubicin Market Revenue and Forecast to 2028 (US$ Thousand)
Europe Epirubicin Market Segmentation
Europe epirubicin market is segmented based on dosage, application, distribution channel, and country
- Based on dosage, the Europe epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held the largest market share in 2022.
- Based on application, the Europe epirubicin market is segmented into breast cancer, liver cancer, bladder cancer, and others. The breast cancer segment held the largest market share in 2022.
- Based on distribution channel, the Europe epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022.
- Based on country, the Europe epirubicin market is categorized into the UK, Germany, France, Italy, Russia, and the Rest of Europe. Further, the UK dominated the market in 2022.
Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Salius Pharma Pvt Ltd, and Teva Pharmaceutical Industries Ltd. are the leading companies operating in the Europe epirubicin market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Epirubicin Market – By Dosage
1.3.2 Europe Epirubicin Market – By Application
1.3.3 Europe Epirubicin Market – By Distribution Channel
1.3.4 Europe Epirubicin Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Epirubicin Market – Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Experts Opinion
5. Europe Epirubicin Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Cancer
5.1.2 Increasing Awareness Regarding Cancer
5.2 Market Restraints
5.2.1 Elevated Risk of Adverse Effects due to Epirubicin
5.3 Future Trends
5.3.1 Increase in Number of Cancer Research Programs
5.4 Impact Analysis
6. Epirubicin Market– Europe Analysis
6.1 Europe Epirubicin Market Revenue Forecasts and Analysis
7. Europe Epirubicin Market Analysis – By Dosage
7.1 Overview
7.2 Europe Epirubicin Market, by Dosage, 2022 & 2028 (%)
7.3 10mg/Vial
7.3.1 Overview
7.3.2 10mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.4 50mg/Vial
7.4.1 Overview
7.4.2 50mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.5 100mg/Vial
7.5.1 Overview
7.5.2 100mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.6 200mg/Vial
7.6.1 Overview
7.6.2 200 Mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
8. Europe Epirubicin Market Analysis – By Application
8.1 Overview
8.2 Europe Epirubicin Market, by Application, 2022 & 2028 (%)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.4 Liver Cancer
8.4.1 Overview
8.4.2 Liver Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.5 Bladder Cancer
8.5.1 Overview
8.5.2 Bladder Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.6 Others
8.6.1 Overview
8.6.2 Others Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
9. Europe Epirubicin Market Analysis – By Distribution Channel
9.1 Overview
9.2 Europe Epirubicin Market, by Distribution Channel, 2022 & 2028 (%)
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
9.5 Online Pharmacies
9.5.1 Overview
9.5.2 Online Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
10. Europe Epirubicin Market – Country Analysis
10.1 Overview
10.1.1 Europe: Epirubicin Market, by Country, 2022 & 2028 (%)
10.1.1.1 Germany: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.1.1 Overview
10.1.1.1.2 Germany: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.1.3 Germany: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.1.1.4 Germany: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.1.1.5 Germany: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.1.1.2 UK: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.2.1 Overview
10.1.1.2.2 UK: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.2.3 UK: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.1.2.4 UK: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.1.2.5 UK: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.1.1.3 France: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.3.1 Overview
10.1.1.3.2 France: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.3.3 France: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.1.3.4 France: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.1.3.5 France: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.1.1.4 Italy: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.4.3 Italy: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.1.4.4 Italy: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.1.4.5 Italy: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.1.1.5 Spain: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.5.3 Spain: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.1.5.4 Spain: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.1.5.5 Spain: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.1.1.6 Rest of Europe: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.1.6.3 Rest of Europe: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.1.6.4 Rest of Europe: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.1.6.5 Rest of Europe: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
11. Industry Landscape
11.1 Overview
11.2 Growth Strategies
11.2.1 Overview
12. Company Profiles
12.1 Pfizer Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Teva Pharmaceutical Industries Ltd.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Salius Pharma Pvt Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Mylan N.V.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Hikma Pharmaceuticals PLC
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Fresenius Kabi AG
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Table 2. Incidence, Mortality and Prevalence by cancer site, 2018, Germany
Table 3. Germany Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 4. Germany: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 5. Germany Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 6. UK Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 7. UK: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 8. UK Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 9. Incidence, Mortality and Prevalence by cancer site, 2018, France
Table 10. France Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 11. France: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 12. France Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 13. Incidence, Mortality and Prevalence by cancer site, 2018, Italy
Table 14. Italy Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 15. Italy: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 16. Italy Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 17. Incidence, Mortality and Prevalence by cancer site, 2018, Spain
Table 18. Spain Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 19. Spain: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 20. Spain Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 21. Rest of Europe Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 22. Rest of Europe: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 23. Rest of Europe Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 24. Recent Growth Strategies
Table 25. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Epirubicin Market Segmentation
Figure 2. Europe Epirubicin Market, By Country
Figure 3. Europe Epirubicin Market Overview
Figure 4. Europe Epirubicin Market, By Dosage
Figure 5. Europe Epirubicin Market, By Country
Figure 6. Europe: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis of Drivers and Restraints on Europe Epirubicin Market
Figure 9. Europe Epirubicin Market – Revenue Forecasts and Analysis
Figure 10. Europe Epirubicin Market, by Dosage, 2022 & 2028 (%)
Figure 11. Europe 10mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 12. Europe 50mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 13. Europe 100mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 14. Europe 200 Mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 15. Europe Epirubicin Market, by Application, 2022 & 2028 (%)
Figure 16. Europe Breast Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 17. Europe Liver Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 18. Europe Bladder Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 19. Europe Others Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 20. Europe Epirubicin Market, by Distribution Channel, 2022 & 2028 (%)
Figure 21. Europe Hospital Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 22. Europe Retail Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 23. Europe Online Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 24. Europe: Epirubicin Market, by Key Country – Revenue (2022) (US$ Thousand)
Figure 25. Europe: Epirubicin Market, by Country, 2022 & 2028 (%)
Figure 26. Germany: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 27. UK: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 28. France: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 29. Italy: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 30. Spain: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 31. Rest of Europe: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- Mylan N.V.
- Pfizer Inc.
- Salius Pharma Pvt Ltd
- Teva Pharmaceutical Industries Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe epirubicin market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe epirubicin market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the epirubicin market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution